CMOPF Stock Latest News
Company AnnouncementsCosmo’s Rifamycin Gel Hits Key Phase 2 Mark in Distal Ulcerative Colitis1w ago
Company AnnouncementsCosmo’s GI Genius AI System Boosts Adenoma Detection in Major VA Study1M ago
Company AnnouncementsCosmo Pharmaceuticals to Change SIX Ticker to CMHC, Aligning Brand With Health-Focused Strategy2M ago- Company AnnouncementsCosmo lifts recurring revenues and advances dermatology and GI pipelines3M ago
- Company AnnouncementsCosmo sets date for 2026 half-year results and investor webcast4M ago
Company AnnouncementsCosmo accelerates European rollout of first-in-class acne drug Winlevi4M ago
Company AnnouncementsCosmo and Glenmark roll out first-in-class acne drug Winlevi across key European markets4M ago
Company AnnouncementsCosmo completes Phase II recruitment for novel ulcerative colitis therapy5M ago
- Company AnnouncementsCosmo’s Clascoterone Delivers Strong 12‑Month Data in Male Hair Loss, Paving Way for 2027 Filings6M ago
- Company AnnouncementsCosmo Shareholders Approve All AGM Resolutions and EUR 2.10 Dividend6M ago
- Company AnnouncementsCosmo to Showcase Real-Time Medical AI Platforms at NVIDIA GTC 20267M ago
Company AnnouncementsCosmo Sets April General Meeting with Name Change and Payout on Agenda7M ago
Company AnnouncementsCosmo Pharmaceuticals Lifts Recurring Revenues, Boosts Dividend and Sets Growth Path to 20307M ago
Company AnnouncementsCosmo teams with Dutch institutions to expand GI Genius AI into Barrett’s esophagus detection8M ago
- Company AnnouncementsCosmo Pharmaceuticals to Court Investors at Major 2026 Healthcare Conferences8M ago
- Company AnnouncementsCosmo Pharmaceuticals Bolsters Institutional Base With Non‑Dilutive Treasury Share Placement9M ago
Company AnnouncementsCosmo Pharmaceuticals Sets 9 March 2026 Webcast for 2025 Full-Year Results9M ago
Company AnnouncementsCosmo Pharmaceuticals Enters Scale-Up Phase on Strong 2025 Results and AI, Dermatology Pipeline Momentum9M ago
